Download full-text PDF |
Source |
---|
Stem Cell Res Ther
January 2025
Department of Medicine, Veterans Affairs Medical Center, Washington, DC, USA.
Introduction: Effects of Dapagliflozin (Dapa) and Dapagliflozin-Saxagliptin combination (Combo) was examined on peripheral blood derived CD34 + Hematopoetic Stem Cells (HSCs) as a cellular CVD biomarker. Both Dapa (a sodium-glucose co-transporter 2 or SGLT2, receptor inhibitor) and Saxagliptin (a Di-peptydl-peptidase-4 or DPP4 enzyme inhibitor) are commonly used type 2 diabetes mellitus or T2DM medications, however the benefit of using the combination has not been evaluated for cardio-renal risk assessment, in a real-life practice setting, compared to a placebo.
Hypothesis: We hypothesized that Dapa will improve the outcomes when compared to placebo and the Combo maybe even more beneficial.
Eur J Med Res
January 2025
Department of Rehabilitation Medicine, The Affiliated Hospital of Yunnan University, No. 176 Qingnian Road, Wuhua District, Kunming, Yunnan, China.
Background: Stress hyperglycemia ratio (SHR) has been linked to prognosis of cerebrovascular diseases. Nevertheless, the association between SHR and severe disturbance of consciousness (DC) and mortality among patients with cerebral infarction remains explored. This study seeks to assess the predictive potential of SHR for severe DC and mortality among patients with cerebral infarction.
View Article and Find Full Text PDFBiochemistry (Mosc)
December 2024
Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
Skeletal muscles account for ~30-40% of the total weight of human body and are responsible for its most important functions, including movement, respiration, thermogenesis, and glucose and protein metabolism. Skeletal muscle damage negatively impacts the whole-body functioning, leading to deterioration of the quality of life and, in severe cases, death. Therefore, timely diagnosis and therapy for skeletal muscle dysfunction are important goals of modern medicine.
View Article and Find Full Text PDFIntroduction There are controversies about whether women with polycystic ovary syndrome (PCOS) show a disproportionately higher visceral adiposity, and its relevance to their higher cardiometabolic risks. We investigated in women of Asian Indian descent in Mauritius, a population inherently prone to abdominal obesity, whether those with PCOS will show a more adverse cardiometabolic risk profile that could be explained by abnormalities in fat distribution. Methods Young women newly diagnosed with PCOS (n=25) were compared with a reference control cohort (n =139) for the following measurements made after an overnight fast: body mass index (BMI), waist circumference (WC), body composition by dual-energy x-ray absorptiometry, blood pressure and blood assays for glycemic (glucose, HbA1c, insulin) and lipid (triglycerides, cholesterols) profiles.
View Article and Find Full Text PDFPurpose: To evaluate the effect of osilodrostat and hypercortisolism control on blood pressure (BP) and glycemic control in patients with Cushing's disease.
Methods: Pooled analysis of two Phase III osilodrostat studies (LINC 3 and LINC 4), both comprising a 48-week core phase and an optional open-label extension. Changes from baseline in systolic and diastolic BP (SBP and DBP), fasting plasma glucose (FPG), and glycated hemoglobin (HbA) were evaluated during osilodrostat treatment in patients with/without hypertension or diabetes at baseline.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!